ReFacto AF Fusengo is a recombinant form of human Factor VIII, a protein that is essential for blood clotting. This medication is specifically designed for the treatment and management of hemophilia A, a genetic disorder characterized by the inability to produce sufficient Factor VIII, leading to prolonged bleeding episodes. ReFacto AF Fusengo works by replacing the missing or deficient Factor VIII, thereby helping the blood to clot normally and preventing bleeding episodes. It is administered through intravenous injection and is used both for routine prophylaxis to prevent or reduce the frequency of bleeding episodes, and to control bleeding when it occurs. This medication is a vital part of hemophilia A management, offering patients the possibility of a more normal life by controlling their bleeding symptoms.